[Effect of S-adenosyl-L-homocysteine of dopamine catabolism].
1.--The administration of SAH to rats, at physiologically active dose on the sleep, does not change the urinary level of MD and NM. On the other hand, the excretion of DA and NA decreases. 2.--In the brain, SAH does not modify neither the concentration of NA and NM in hypothalamus and thalamus, nor the concentration of DA and MD in corpus striatum. 3.--After intracisternally injection of [14C]DA or [3H]NA, SAH increases the level of [14C]MD and [3H]NM. 4.--Contrary to the studies in vitro, where SAH is an inhibitor of COMT, on the rat it does not seem prevent the methylation of DA and NA.
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D003342:Corpus Striatum / Q000378:metabolism; D003846:Deoxyepinephrine / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D006710:Homocysteine / Q000031:analogs & derivatives*; D007031:Hypothalamus / Q000378:metabolism; D008297:Male; D008780:Methyltransferases / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D009647:Normetanephrine / Q000378:metabolism; D009928:Organ Specificity; D051381:Rats; D012435:S-Adenosylhomocysteine / Q000494:pharmacology*; D013788:Thalamus / Q000378:metabolism
D009647:Normetanephrine; D006710:Homocysteine; D012435:S-Adenosylhomocysteine; D008780:Methyltransferases; D003846:Deoxyepinephrine; D004298:Dopamine; D009638:Norepinephrine
Effet de la S-adenosyl-L-homocysteine sur le catabolisme de la dopamine.